Eikon Therapeutics

About:

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

Website: http://www.eikontx.com

Twitter/X: eikontx

Top Investors: StepStone Group, General Catalyst, Lux Capital, Schroders Capital, Innovation Endeavors

Description:

Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.

Total Funding Amount:

$772M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Hayward, California, United States

Founded Date:

2019-01-01

Contact Email:

kheterpala(AT)eikontx.com

Founders:

Eric Betzig, Luke Lavi, Robert Tjian, Xavier Darzacq

Number of Employees:

251-500

Last Funding Date:

2023-06-01

IPO Status:

Private

© 2025 bioDAO.ai